Crowding in Biotech Development

  • “An analysis of biopharma pipelines shows that the average number of assets per target investigated has more than doubled: 3 assets/target in 2000 to 7/target today. The number of assets in clinical development is outpacing the number of biological approaches, particularly in oncology.”
  • Source.

AI Moat

  • This leaked memo from Google has been doing the rounds last two weeks.
  • The jist is that no one has a moat in AI.
  • The arguments boil down to the idea that there has been so much innovation that open source will win.
  • Ben Thompson lists a few counterarguments about why this might not be true.
  • The other point, mentioned by a friend, is having intellectual property infringement experience as a key competitive advantage.
WordPress Cookie Notice by Real Cookie Banner